Claims
- 1. A method of reducing an ocular disease comprising implanting, in the eye of a subject in need of such treatment, a composition comprising an effective amount of encapsulated cells, wherein said encapsulated cells are encapsulated with a biocompatible material of polyacrylonitril-methallylsulfonate, and wherein said encapsulated cells produce a neurotropic or an anti-angiogenic polypeptide for reducing said ocular disease.
- 2. The method according to claim 1, wherein said biocompatable material forms a biocompatible microcapsule which prevents entry of host immune cells inside said encapsulated cells and releases said neurotropic or anti-angiogenic polypeptide outside of the microcapsule.
- 3. The method according to claim 2, wherein said biocompatible microcapsule is made of a biocompatible material which is permeable or semi-permeable material with pores having an internal diameter below 400 μm.
- 4. The method according to claim 1, wherein said neurotropic or an anti-angiogenic polypeptide is a human fibroblast growth factor or a human endostatin.
- 5. The method according to claim 1, wherein said biocompatable material forms a biocompatible microcapsule and comprise mammalian cells comprising a genome which has been genetically modified with a nucleic acid fragment encoding said neurotropic or anti-angiogenic polypeptide.
- 6. The method according to claim 5, wherein said mammalian cells are selected from the group of fibroblast, muscle cells, hepatocytes, neural cells, kidney cells, astrocytes and MDCK cells.
- 7. The method according to claim 1, wherein said ocular disease is selected from the group of tumor, ocular degenerations, retinopathies and retinitis.
- 8. The method according to claim 1, wherein said ocular disease is age-related macular degeneration.
- 9. A method of reducing an ocular disease comprising administering to a subject in need of such treatment a composition comprising an effective amount of human fibroblast growth factor secreting fibroblast cells encapsulated with a biocompatible material of polyacrylonitril-methylsulfonate.
- 10. The method according to claim 9, wherein said human fibroblast growth factor secreting fibroblast cells are mouse fibroblast class (NIH3T3) stably transfected with plasmid pSFGF18.
- 11. A method reducing photoreceptor cell degeneration comprising the step of administering intraocularly to a subject in need of such treatment a composition comprising an effective amount of encapsulated cells, wherein said encapsulated cells are encapsulated with a biocompatible material of polyacrylonitril-methallylsulfonate, and wherein said encapsulated cells produce a neurotropic or anti-angiogenic polypeptide.
- 12. The method according to claim 11, wherein said biocompatable material forms a biocompatible microcapsule which prevents entry of host immune cells inside said encapsulated cells and releases said neurotropic or anti-angiogenic polypeptide outside of the microcapsule.
- 13. The method according to claim 11, wherein said neurotropic or anti-angiogenic polypeptide is a human fibroblast growth factor or a human endostatin.
- 14. The method according to claim 11, wherein said biocompatable material forms a biocompatible microcapsule and comprise mammalian cells comprising nucleic acid encoding said neurotropic or anti-angiogenic polypeptide.
- 15. The method according to claim 14, wherein said mammalian cells are selected from the group of fibroblasts, muscle cells, hepatocytes, neural cells, kidney cells, astrocytes and MDCK cells.
- 16. A method of reducing photoreceptor cell degeneration comprising administering to a subject in need of such treatment a composition comprising an effective amount of human fibroblast growth factor secreting fibroblast cells encapsulated with a biocompatible material of polyacrylonitril-methylsulfonate.
Parent Case Info
This application is a divisional of application Ser. No. 09/449,293, filed Nov. 24, 1999, now U.S. Pat. No. 6,267,954, which application(s) are incorporated herein by reference.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
5374616 |
Spiegel et al. |
Dec 1994 |
A |
5904144 |
Hammang et al. |
May 1999 |
A |
6299895 |
Hammang et al. |
Oct 2001 |
B1 |
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO 9734586 |
Sep 1997 |
WO |
Non-Patent Literature Citations (2)
Entry |
Serguera, C. et al., “Control of Erythropoietin Secretion by Doxycycline or Mifepristone in Mice Bearing Polymer-Encapsulated Engineered Cells”, Human Gene Therapy, 10:375-383 (Feb. 10, 1999). |
Uludag, H. et al., “Technology of mammalian cell Encapsulation”, Advanced Drug Delivery Review, 20:29-64 (2000). |